Organic Active Ingredients TRIZ Cases

DNA methyltransferase inhibitors reduce DNA methylation to slow calcific aortic valve stenosis progression.

Brittle matrix particles combine salmeterol and mometasone into unified structures for inhalation therapy.

Sulindac agents protect retinal pigment epithelium cells by activating protective pathways to counter photooxidative damage.

Chemical necrosis of submental fat via sodium deoxycholate replaces invasive liposuction, reducing surgical risks while maintaining treatment effectiveness.

Saturated tau ligands bind protein aggregates without photoisomerizable double bonds.

Alstonine formulation modulates IL-17 and IL-12/23 pathways to reduce inflammation while avoiding adverse side effects from broad-spectrum therapies.

Isotopic substitution in a benzofuran methanone crystalline form reduces hepatotoxicity while maintaining URAT1 potency.

A quinazoline compound activates BKCa channels to induce bladder smooth muscle relaxation.

Targeting VPS4A or VPS4B expression overcomes therapeutic limitations in neoplasia characterized by reduced protein levels.

Tricyclic compounds act as selective M4 allosteric modulators to improve cognitive function while avoiding peripheral side effects.

N1-cyclic amine-N5-substituted biguanide derivatives activate AMPK to inhibit cancer cell proliferation and metastasis.

Segmented copolymer nanoparticles maintain high local antibiotic concentrations while reducing systemic toxicities.

Modified isoleucine zipper domains stabilize TRAIL trimers, extending serum half-life and reducing immunogenicity for cancer therapy.

A polymer composition derived from Bacillus licheniformis inhibits viral replication and entry mechanisms.

Antisense oligonucleotides target retained intron sequences to modify RNA splicing, treating diseases caused by insufficient protein expression.

Formula I pyrrole compound targets low NNMT and high UHRF1 expression to treat heterogeneous tumors effectively.

Segmenting yohimbine into modular components allows systematic generation of diverse analogs to address limited productivity in drug development.

Combining turmeric, sacha inchi, and cannabidiol oils addresses speech and motor deficits where single therapies fail.

Preliminary AON administration stabilizes viral vector genomes while GDF5 signaling increases muscle mass to resolve rapid genome loss.

SHetA2 and PRIMA-1MET drug combinations restore p53 activity to inhibit ovarian cancer recurrence while minimizing side effects.

Imidazopyridine carboxamides modulate Nurr-1 nuclear receptors via specific phenyl substitutions.

Fused bicyclic heteroaryl compounds inhibit MALT-1 to reduce NF-kB signaling in proliferative disorders.

Sustained release formulation delivers cytostatic drug to prostate tissue via catheter, eliminating systemic side effects from oral medications.

Synergizes MDM2 inhibition with immunotherapy to convert resistant tumors into responding ones.

A novel anti-inflammatory compound with specific structural modifications targets immune cell activity and cytokine release pathways.

A topical podophyllotoxin emulsion delivers active ingredients to skin surfaces.

Merges nitazoxanide and ribavirin into a single tablet to achieve synergistic viral inhibition while maintaining monotherapy safety profiles.

Selective CDPK1 inhibitors eradicate chronic toxoplasmosis while avoiding severe toxicity.

Compound B maintains antitumor efficacy against resistant Bcl-2 mutations like Gly101Val through distinct binding modes.

Dry powder formulations of 5-MeO-DMT with silicon dioxide prevent liquid stability issues and discolouration while maintaining pharmacokinetic properties.

Merges fumarate and oxidoreductase peptides to induce tolerance and reduce autoimmune disease activity.

Intrathecal PLGA-encapsulated pDNA-IL-10 elevates IL-10 levels, addressing pro-inflammatory mechanisms that current treatments fail to resolve.

Stabilized psilocin salts enable rapid oral disintegration, bypassing slow metabolic conversion to deliver consistent therapeutic onset.

Oral 3-IAld pharmaceutical composition maintains epithelial barrier integrity in patients with CTLA-4 checkpoint related immunodeficiencies.

Clustering lymphoma patients by gene expression levels to predict treatment responsiveness.

A segmented mixing vessel uses insulator and metal segments to neutralize powder charges during blending.

A segmented bolus releases medication through sequential tablet erosion to match animal growth rates.

Methyl cyclodextrins form inclusion complexes with lipids to reduce liver storage.

Structural optimization of cyclic diarylthioureas achieves sub-nanomolar potency while reducing toxicity in prostate cancer treatment.

A topical cream combines beta-caryophyllene with phospholipids and triglycerides to deliver multi-component therapy.

Compounds inhibit JAK kinases and PDK1, disrupting signaling pathways to treat myeloproliferative disorders.

Inhaled ultrarapid insulin mimics early-phase secretion to control postprandial glucose while reducing hypoglycemia risk.

Combining CK-2017357 with riluzole reduces serum concentration variability, enabling lower daily doses while minimizing adverse events in ALS treatment.